创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: What are the features and advantages of ADCC platforms

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-30 14:37
  • Views:

(Summary description)In the field of biomedicine, antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism in tumor immunotherapy. In order to meet the growing research needs, InnoModels Biotechnology has successfully built an in vitro pharmacodynamics platform, of which the ADCC platform has been widely recognized by the industry for its unique features and advantages.

InnoModels Biotechnology: What are the features and advantages of ADCC platforms

(Summary description)In the field of biomedicine, antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism in tumor immunotherapy. In order to meet the growing research needs, InnoModels Biotechnology has successfully built an in vitro pharmacodynamics platform, of which the ADCC platform has been widely recognized by the industry for its unique features and advantages.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-05-30 14:37
  • Views:
Information

In the field of biomedicine, antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism in tumor immunotherapy. In order to meet the growing research needs, InnoModels Biotechnology has successfully built an in vitro pharmacodynamics platform, of which the ADCC platform has been widely recognized by the industry for its unique features and advantages.
InnoModels' ADCC platform has a diversified experimental service system, which is mainly reflected in its ability to support a variety of types of tumor cells and immune cells in combination experiments. Whether it is tumor cell lines, primary tumor cells or genetically engineered cell lines, the platform can provide appropriate experimental conditions and technical support. Similarly, for effector cells, the platform supports commercially-sourced PBMC (peripheral blood mononuclear cells) as well as clinical patient-sourced PBMC, which provides a rich selection space for researchers to choose the most appropriate cell type according to specific research needs.

 


In terms of experimental design, InnoModels' ADCC platform focuses on simulating the in vivo environment to more realistically reflect the actual situation of the ADCC process. The platform adopts advanced cell culture technology and flow cytometry technology, which can monitor and record the changes of cells in real-time during the experimental process, effectively differentiate between target cells, count and calculate the proportion of apoptotic cells, and provide researchers with accurate and reliable data support.
It is worth mentioning that InnoModels' ADCC platform is also highly customizable. The platform can be customized according to the specific needs of the researcher, including cell type, drug treatment, experiment time and other aspects. This flexibility enables the platform to meet the diverse needs of different researchers, providing powerful technical support for biomedical research.
In addition, InnoModels' ADCC platform has efficient data processing capabilities. Equipped with an advanced data analysis system, the platform is able to automate the processing and analysis of experimental data, greatly improving the efficiency and accuracy of data processing. Researchers can intuitively understand the experimental results through the visualization reports provided by the platform, thus better guiding the subsequent research work.
Overall, InnoModels' ADCC platform provides powerful technical support for biomedical research with its diverse experimental services, realistic simulation environment, high degree of customizability, and efficient data processing capabilities. In the future, with the continuous development of the biomedical field, InnoModels' ADCC platform will play a greater role in promoting the progress of biomedical research.  

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司